Eng-Huat Tan

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 953 citations

Medicine, Oncology, Pharmacology +10

Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma

Anne W.M. Lee, Stewart Y. Tung, Anthony T.�C. Chan et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 157 citations

Medicine, Oncology, Radiation Oncology +15

A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma

Anne W.M. Lee, Stewart Y. Tung, Anthony T.�C. Chan et al. · Radiotherapy and Oncology · 2010 · 108 citations

Medicine, Oncology, Chemotherapy +13

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Balázs Halmos, Eng-Huat Tan, Ross A. Soo et al. · Lung Cancer · 2018 · 76 citations · Full text

Pharmacy, Oncology, Pharmacology +15